| CRL |
Report |
Adjusted EPS (2026Q2) |
BEAT |
pred ~$2.82 vs. cons $2.73 |
MEDIUM |
| CRL |
Report |
Revenue (2026Q2) |
IN-LINE |
pred ~$972.0M vs. cons $974.7M |
MEDIUM |
| CRL |
Report |
DSA net book-to-bill (2026Q2) |
IN-LINE |
pred ~1.01x vs. cons 1.00x |
LOW |
| CRL |
Guide |
Adjusted EPS guidance |
LOWER |
guide ~$11.05 vs. cons $11.11 (FY2026) |
MEDIUM |
| CRL |
Guide |
Revenue guidance |
LOWER |
guide ~$3.82B vs. cons $3.85B (FY2026) |
MEDIUM |
| CRL |
Guide |
Adjusted operating-margin expansion guidance |
UNCHANGED |
guide ~135 bps vs. cons 135 bps (FY2026) |
MEDIUM |
| CRL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.2% |
— |
MEDIUM |
| CRL |
Return |
5-day cumulative residual |
-6.5% (FOLLOW-THROUGH) |
An EPS beat of ~$0.09 versus consensus but unchanged FY2026 EPS guidance implies only ~$6.17 of 2026H2 EPS versus the prior consensus-implied ~$6.32, prompting out-period estimate cuts despite the headline beat. |
MEDIUM |